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Abstract 
Background: There are scarce studies on the management of glucose 6-phosphate 
dehydrogenase (G6PD) deficient patients during cardiac surgery. The purposes of 
this retrospective study were to present and evaluate our experience with G6PD 
deficient patients who underwent cardiac surgery with cardiopulmonary bypass 
(CPB). 
Methods: We included 20 patients with G6PD deficiency who had cardiac surgeries 
from 2015 to 2019. We used free radical scavenging strategy and careful 
perioperative management. The patients were compared to a control group of 20 
patients with normal G6PD enzyme activity who underwent the same type of 
operations in the same period. 
Results: Males represented 80% of G6PD deficient patients. There were significant 
elevations in preoperative total bilirubin (1.03±0.33 vs. 0.57±0.11 mg/dl, p< 0.001) 
and reticulocytes (1.87±0.62 vs. 0.54±0.18%) in G6PD deficient patients. Valve 
surgery was done for 60% of G6PD deficient patients. There were no significant 
differences between both groups regarding the type of surgery, aortic cross-clamp, 
CPB, and total operative time. G6PD deficient patients had significantly lower 
postoperative hemoglobin levels (9.44±0.94 vs. 10.0±0.59 g/dl, p= 0.04) and 
significantly higher postoperative total bilirubin (1.51±0.51 vs. 0.98±0.45 mg/dl; 
p=0.002) and reticulocytes (1.85±0.51 vs. 0.57±0.13%; p< 0.001). There was no 
significant difference regarding postoperative urea and creatinine levels. Ventilation 
time (10.3±2.7 vs. 8.2±1.9 hours; p=0.01), ICU stay (3.1±0.87 vs. 2.3±0.71 days; 
p=0.004), and hospital stay (3.1±0.87 vs. 6.0±1.02 days; p<0.001) significantly 
increased in G6PD deficient patients. The mortality rate was 5% (one patient) in 
G6PD deficient patients.  
Conclusion: Despite the management strategy, G6PD deficient patients undergoing 
cardiac surgery are more liable to hemolysis and hypoxia with more need for blood 
transfusion and longer ventilation time, ICU, and hospital stays when compared to 
patients with normal G6PD enzyme activity. Further research to improve the 
outcomes in G6PD deficient patients is required. 
KEYWORDS 
G6PD deficiency; 
Cardiopulmonary 
bypass; Free radical 
scavengers; Mannitol; 
Allopurinol hemolysis 
In Pr
s
36 
Introduction 
Glucose 6-Phosphate Dehydrogenase (G6PD) 
deficiency is an X-linked genetic disorder.  It is 
prevalent in Sub-Saharan Africa, the Middle East, 
and Asia [1]. The prevalence of G6PD deficiency 
in the Sultanate of Oman is high, 25% in males, 
and 10% in females [2]. G6PD deficiency leads to 
a decrease in reduced glutathione production, 
which will not be enough to protect cells from 
oxidative stress. Consequently, the cell membrane 
bursts (hemolysis), which may be a deadly matter 
[3-6]. G6PD deficiency potentiates the harmful 
effect of free radicals [7-9].  
The World Health Organization (WHO) [10] 
classified G6PD genetic variants into five classes. 
Perioperative ischemia, contact of blood with 
circuit tubes, hypothermia, hypoperfusion, 
acidosis, and reperfusion, that involved in cardiac 
surgery with cardiopulmonary bypass (CPB) 
potentiate the harmful effect of free radicals in 
G6PD deficient patients [3,11,12].  
The studies on G6PD deficient patients 
undergoing CPB are rare. The study aims to 
present and evaluate the efficacy of perioperative 
strategies that we used to minimize hemolysis for 
G6PD deficient patients undergoing open-heart 
surgeries on cardiopulmonary by using mannitol 
and allopurinol as free radical scavengers and 
avoidance drugs that suspected to trigger 
hemolysis of red corpuscles. 
Patients and Methods: 
This retrospective observational study was 
conducted on 20 patients who had moderate to 
severe form of G6PD deficiency (WHO class I, II, 
and III). We compared patients with G6PD 
deficiency to 20 patients with normal G6PD 
enzyme activity (control group). All patients 
underwent cardiac surgery using cardiopulmonary 
bypass (CPB) between January 2015 and April 
2019. We did not exclude any patient with G6PD 
deficiency. None of our patients had recent 
hemolytic crises. The selection of the patients in 
the control group (20 patients) was performed 
from 956 patients with normal G6PD enzyme 
activity who operated at the same period using 
our computerized database considering age, sex, 
type of operation, and comorbidities.  
All data were retrospectively collected, 
including history, and laboratory investigations 
(preoperative and daily postoperative 
hemoglobin, hematocrit, bilirubin, reticulocyte 
count, creatinine, and blood urea). The protocol 
used for G6PD deficiency patients A 
multidisciplinary team from cardiac surgeons 
and hematologists managed and followed 
the patients from admission until hospital 
discharge. 
Preoperative: 
Good urinary flow was maintained using 
intravenous mannitol 0.5 g/kg once daily and 
Furosemide 10mg thrice daily to prevent any renal 
tubular injury due to free hemoglobin. Allopurinol 
600mg was given orally in the preoperative night 
and repeated 2 hours before surgery. 
Operative: 
Patients were premedicated with 
glycopyrrolate. Anesthesia was induced with 
propofol and fentanyl. Atracurium was given to 
facilitate tracheal intubation, and anesthesia was 
maintained with isoflurane in 100% oxygen, 
incremental doses of atracurium, and mechanical 
ventilation. 
CPB was conducted using a roller pump with 
minimum occlusion to avoid hemolysis.  Albumin 
was added in the prime solution for coating the 
CPB circuit to prevent the initiation of the 
complement cascade. Intermittent warm, bold 
cardioplegia was given every 20 minutes. The 
temperature was maintained 32-34˚c during 
bypass. Blood pressure was maintained around 70 
mmHg. Urine output was maintained with the use 
of mannitol 100ml and furosemide 20mg. Two 
units of Fresh-frozen plasma (FFP) and four units 
of platelets were given immediately after weaning 
from CPB. No antifibrinolytic agent such as 
tranexamic acid was used. Operative data 
included CPB, aortic cross-clamp, and operative 
time were recorded.  
Postoperative: 
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Patients were transferred to ICU on a 
mechanical ventilator. Investigations were done 
to assess hemolysis; hemoglobin, hematocrit, 
reticulocyte count, bilirubin, urea, and creatinine. 
Fentanyl 2 um/kg/h was used for postoperative 
analgesia in the 1st 24 hours. Adrenaline, 
noradrenaline, and nitroglycerine were given 
according to hemodynamics, and amiodarone for 
atrial fibrillation (AF) control was used when 
needed. The standard protocol for postoperative 
fluid and blood transfusion was used for both 
groups of patients. Blood transfusion was used for 
patients with significant chest drainage associated 
with hemodynamic instability, when hemoglobin 
value less than 10 g/dL with associated symptoms 
related to anemia, or when hemoglobin value less 
than 8 g/dL. 
Total drainage in chest drains in 24 hours was 
recorded, and the number of blood units required 
postoperatively was recorded. 
Our protocol for the management of G6PD 
deficient patients includes avoidance of drugs 
listed in Table 1 and Table 2. 
Table 1: Drugs to be avoided for G6PD deficient 
patients [13] 
Drugs to be avoided for G6PD deficient 
patients, Bubp et al., 2015 [13] 
Dapsone Phenazopyridine 
Flutamide Primaquine 
Furazolidone Rasburicase 
Isobutyl nitrite Nitrofurantoin 
Methylene blue Phenazopyridine 
Niridazole Primaquine 
Endpoints 
The primary endpoints were postoperative 
hemoglobin value, hematocrit percent, bilirubin 
level, reticulocyte count, creatinine, and blood 
urea immediate postoperative and in the first 
seven days postoperative. The secondary 
endpoints were ventilation time, and total 
drainage in chest drains in 24 hours. The 
postoperative complications and outcome, 
including ICU stay and total hospitalization time, 
were also recorded. 
Statistical analysis: 
All statistical analyses were done using IBM 
SPSS for Windows, Version 22.0 (IBM Corp., 
Armonk, NY, USA). According to the type of data, 
qualitative data represented as number and 
percentage and quantitative data represented by 
means ± standard deviation (SD). Quantitative 
variables were compared using a t-test or Mann–
Whitney test if not normally distributed, and 
qualitative variables were compared using the Chi-
square test or Fischer's Exact test if the frequency 
of the events is less than 5. P-value was set at 
<0.05 for significant results. 
Results 
Males represent 80% of G6PD deficient 
patients. There were no significant differences 
between the G6PD deficiency group and the 
control group regarding age, sex, NYHA functional 
class, and comorbidities (diabetes mellitus, and 
chronic obstructive pulmonary disease). (table 3). 
No preoperative differences between both groups 
regarding hemoglobin level, hematocrit percent, 
blood urea, and serum creatinine (p = 0.086, 
0.092, 0.192 and 0.098 respectively), while there 
Table 2: Drugs to be used with caution in therapeutic doses for G6PD deficient patients [13] 
Drugs to be used with caution in therapeutic doses for G6PD deficient patients, Bubp et al., 2015 [13] 
Acetaminophen Chloroquine Sulfacytine 
Acetylsalicylic acid Colchicine Sulfadiazine 
Antazoline Diphenhydramine Sulfaguanidine 
Antipyrine Glyburide Sulfamethoxazole 
Ascorbic acid: IV doses only reported Isoniazid Sulfisoxazole 
Benzhexol L-Dopa Trimethoprim 
Chloramphenicol Quinine Tripelennamine 
Chlorguanidine Streptomycin Vitamin K 
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Table 3: Preoperative data in both groups 
Variables G6PD deficiency Group (n = 20) Control Group (n = 20) P 
Age, y 52.0±6.77 51.6±5.85 0.843 
Male sex, n (%) 16 (80%) 14 (70%) 0.465 
NYHA FC 
I 5 (25%) 4 (20%) 0.500 
II 6 (30%) 6 (30%) 0.634 
III 7 (35%) 8 (40%) 0.500 
IV 2 (10%) 2 (10%) 0.697 
WHO Class 
I 3 (15%) - 
II 10 (50%) - 
III 7 (35%) - 
DM 13 (65%) 12 (60%) 0.743 
COPD 5 (25%) 4 (20%) 0.500 
Hemoglobin (g/dl) 13.84±1.4 14.46±0.6 0.086 
Hematocrit (%) 41.1±4.1 42.94±2.2 0.092 
Total 
Bilirubin(mg/dl) 
1.03±0.33 0.57±0.11 <0.001 
Reticulocyte (%) 1.87±0.62 0.54±0.18 <0.001 
Urea (mg/dl) 16.8±3.4 15.5±2.8 0.192 
Creatinine(mg/dl) 1.01±0.12 0.94±0.14 0.098 
NYHA FC = New York Heart Association Functional Class, WHO Class = World Health Organization G6PD 
deficiency Class, DM = diabetes mellitus, COPD = chronic obstructive pulmonary disease 
were significant elevations in preoperative total 
bilirubin and reticulocytes in G6PD deficient 
patients (p <0.001, for both). (Table 3) 
Operative results 
CABG was done for 40% of G6PD deficient 
patients with a mean of 2.5±0.8 graft per patient. 
LIMA to LAD was done for all patients in both 
groups. Valve surgery was done for 60% of G6PD 
deficient patients.  Mitral valve repair was done 
for four patients in the G6PD deficiency group 
versus two patients in the control group. Valve 
replacement with mechanical valve prosthesis was 
done for replacing mitral and aortic valves in the 
rest of the patients.
Table 4: Operative data of both groups 
Variables G6PD deficiency Group (n = 20) Control Group (n = 20) P 
Type of surgery 
CABG 8(40%) 8(40%) 0.626 
Graft/patient 2.5±0.8 2.4±0.8 0.694 
Valve Surgery 12 (60%) 12 (60%) 0.626 
AVR 3 (15%) 3 (15%) 
AVR+MVR 1 (5%) 1 (5%) 
MV Repair 2 (10%) 2 (10%) 
MVR 2 (10%) 2 (10%) 
MVR+TV Repair 4 (20%) 4 (20%) 
ACC time(min) 68.3±10.5 64.6±12.2 0.239 
CPB time(min) 125.6±15.4 115.9±23.5 0.132 
Operative time(min) 171.4±49.9 156.8±42.4 0.401 
CABG = coronary artery bypass grafting, AVR = Aortic valve replacement, MVR = Mitral valve 
replacement, TV = Tricuspid valve, ACC = Aortic-cross clamp, CPB= Cardiopulmonary bypass. 
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There were no significant differences between 
both groups regarding the type of surgery, aortic-
cross clamp time, CPB time, and total operative 
time. (Table 4) 
Postoperative results 
G6PD deficient patients had significantly lower 
hemoglobin levels (HB) and hematocrit values 
(HCT) at all the six days post-operation. In the 7th 
postoperative day, there were no significant 
differences between both groups, but their 
values did not reach the preoperative levels. 
(Table 1,Table 5) 
G6PD deficient patients had significantly 
higher total bilirubin (TB) and reticulocytes at all 
the seven days post-operation. At the same time, 
the differences between both groups regarding 
urea and creatinine levels were not significant all 
the time. (Table 6,Table 7) 
Ventilation time was significantly higher in 
G6PD deficient patients than control patients 
(10.3±2.7 Vs. 8.2±1.9 hours, P = 0.01). Also, 
drainage volume was significantly more in G6PD 
deficient patients than control patients 
(750.1±136.6 Vs. 532.5±154.1 mL, P <0.001). The 
need for blood transfusion was more in G6PD 
deficient patients (1.9±1.4 Vs. 0.8±1.0 
unit/patient, P <0.001). The maximal and the 
minimal partial pressure of arterial oxygen (Max 
PaO2 and Min PaO2) in ICU were significantly 
lower in G6PD deficient patients (P <0.001 and P 
<0.001 respectively). ICU stay, and hospital stay 
was longer in G6PD deficient patients than control 
patients (p = 0.004 and P <0.001, respectively). 
(Table 8) 
In both groups of patients, there was one case 
of mortality in the G6PD deficiency group, a 
patient suffering from rheumatic severe aortic 
incompetence and severe mitral incompetence 
with low ejection fraction (EF = 34%), aortic and 
mitral valve replacement was done for him. The 
patient could not be weaned from CPB due to left 
ventricular failure. 
Discussion 
Glucose-6- phosphate dehydrogenase 
deficiency is a genetic X-linked recessive disorder 
that occurs almost exclusively in males. The usual 
clinical presentations are the consequences of 
hemolysis that include anemia, jaundice, 
hepatosplenomegaly, and reticulocytosis [7]. In 
hexose monophosphate pathway of glucose 
metabolism, G6PD reduce nicotinamide adenine
Table 5: Postoperative HB level and hematocrit value for both groups 
Variables G6PD deficiency Group (n = 19) Control Group (n = 20) P 
HB g/dL 
Immed. PO  10.1±0.57 10.5±0.45 0.021 
1st_POD 9.44±0.94 10.0±0.59 0.036 
2nd_POD 9.84±0.76 10.48±0.47 0.003 
3rd_POD 9.56±0.48 10.74±0.65 0.004 
4th_POD 9.81±0.87 11.08±0.58 <0.001 
5th_POD 10.5±1.14 11.2±0.59 0.028 
7th_POD 10.91±1.39 11.2±0.41 0.397 
Hematocrit (%) 
Immed.PO  30.3±2.33 32.1±2.12 0.016 
1st_POD 28.1±3.31 30.1±2.79 0.047 
2nd_POD 28.4±2.15 30.6±2.25 0.003 
3rd_POD 28.6±1.67 30.7±1.99 0.001 
4th_POD 29.5±1.79 31.2±2.01 0.008 
5th_POD 31.6±1.97 33.2±1.37 0.005 
7th_POD 32.8±3.93 31.72±1.53 0.401 
HB = hemoglobin, Immed.PO= Immediate postoperative, POD = postoperative day, HCT = hematocrit 
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Table 6: Postoperative total bilirubin and reticulocytes for both groups 
Variables G6PD deficiency Group (n = 19) Control Group (n = 20) P-value 
T Bilirubin(mg/dl) 
Immed.PO  1.37±0.39 1.02±0.31 0.004 
1st_POD 1.51±0.51 0.98±0.45 0.002 
2nd_POD 2.06±0.69 0.91±0.35 <0.001 
3rd_POD 2.24±0.75 0.85±0.24 <0.001 
4th_POD 1.91±0.63 0.76±0.19 <0.001 
5th_POD 1.51±0.51 0.67±0.15 <0.001 
7th_POD 1.21±0.40 0.63±0.15 <0.001 
Reticulocyte (%) 
Immed.PO  1.74±0.57 0.59±0.19 <0.001 
1st_POD 1.85±0.51 0.57±0.13 <0.001 
2nd_POD 2.05±0.63 0.62±0.202 <0.001 
3rd_POD 2.22±0.72 0.57±0.19 <0.001 
4th_POD 2.18±0.74 0.51±0.18 <0.001 
5th_POD 2.08±0.73 0.55±0.18 <0.001 
7th_POD 1.9±0.64 0.54±0.17 <0.001 
T Bilirubin = Total Bilirubin, Immed.PO= Immediate postoperative POD = post-operative day 
dinucleotide phosphate (NADP) to reduced 
nicotinamide adenine dinucleotide phosphate 
(NADPH). NADPH reduces oxidized glutathione to 
reduced glutathione, which protects cells from 
oxidative damage. Deficiency in G6PD leads to a 
decrease in reduced glutathione production, 
which will not be enough to protect cells from 
oxidative stress that will be very critical in the case 
of red blood cells due to the absence 
of mitochondria [3-5]. 
The two standard tests for diagnosis of G6PD 
deficiency are the Beutler test and the 
quantitative spectrophotometric analysis test. The 
rapid Beutler fluorescent spot test detects the 
generation of NADPH from NADP. Failure of the 
blood spot to fluoresce under ultraviolet light 
indicates a positive test. 
Table 7: Postoperative blood urea and serum creatinine for both groups of patients 
Variables G6PD deficiency Group (n = 19) Control Group (n = 20) P-value 
Urea (mg/dl) 
Immed.PO  18.2±5.08 20.6±5.41 0.160 
1st_POD 20.9±3.82 22.1±4.62 0.380 
2nd_POD 22.3±4.08 23.1±3.71 0.527 
3rd_POD 19.8±4.14 20.6±3.57 0.525 
4th_POD 19.4±4.28 21.2±4.05 0.187 
5th_POD 22.3±7.71 20.0±3.65 0.248 
7th_POD 18.9±4.47 19.7±2.72 0.515 
Creatinine(mg/dl) 
Immed.PO  1.08±0.13 1.11±0.15 0.509 
1st_POD 1.07±0.18 1.11±0.06 0.375 
2nd_POD 0.94±0.07 1.0±0.21 0.235 
3rd_POD 0.91±0.06 0.95±0.18 0.352 
4th_POD 0.90±0.08 0.95±0.17 0.249 
5th_POD 0.86±0.11 0.9±0.14 0.326 
7th_POD 0.82±0.07 0.85±0.06 0.161 
Immed.PO= Immediate postoperative POD = post-operative day 
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Table 8: Intensive care (ICU) and ward data of both groups 
Variables G6PD deficiency Group (n = 19) Control Group (n = 20) P 
Ventilation time(hr.) 10.3±2.7 8.2±1.9 0.01 
Max PaO2 (mm Hg) 410.7±20.0 461.2±15.2 <0.001 
Min PaO2 (mm Hg) 67.0±6.9 89.0±12.8 <0.001 
Drainage volume(mL) 750.1±136.6 532.5±154.1 <0.001 
Blood Transfusion (Unit/patient) 1.9±1.4 0.8±1.0 <0.001 
ICU stay (days) 3.1±0.87 2.3±0.71 0.004 
Hospital stay (days) 8.7±1.41 6.0±1.02 <0.001 
Mortality 1 (5%) 0 0.50 
hr. = hours, Max PaO2 = maximal partial pressure of arterial oxygen, Min PaO2= minimal partial pressure of 
arterial oxygen, ICU = intensive care unit 
The quantitative spectrophotometric analysis 
of G6PD activity in a leukocyte-depleted sample is 
considered as the standard quantitative test [3- 5,
14]. 
G6PD deficient patients are very sensitive to 
oxidative stress when exposed to certain 
precipitating medications, certain foods, certain 
chemicals, infection, and extracorporeal 
circulation [10, 15,16]. 
CPB has mechanical damaging factors (roller 
pumps, cardiotomy suction, and circuit tubes) and 
it potentiates systemic inflammation through the 
production of oxygen free radicals, both can result 
in red cell lysis and endothelial injury. These 
effects are exaggerated in G6PD deficient 
patients due to their high sensitivity to oxidative 
stress [3, 11,12]. Although Altikat and colleagues 
[17] in an in-vitro study reported that isoflurane, 
sevoflurane, diazepam, and midazolam had an 
inhibitory effect on G6PD activity, there is no 
sufficient in-vivo research data supporting this 
concept. On the other hand, anesthetic agents like 
isoflurane, sevoflurane, fentanyl, and rocuronium 
were used safely in G-6-PD deficiency patients 
[3,11,18,19], and our experience supports this 
view. 
The free radical scavengers such as mannitol 
and allopurinol can minimize the free radical 
generation by decreasing the effect of oxidative 
stress on the cells [6, 20, 21]. Our protocol for 
managing G6PD deficiency patients in this study 
included the use of mannitol and allopurinol as 
free radical scavengers. Chowdhry and 
collaborators [11] and Kumar [3] used the same 
strategy. 
Mannitol has an osmotic diuretic effect and 
free radical scavenging properties that can 
reduce the extent of ischemic injury [22]. Besides, 
the main usage of allopurinol is to compete with 
the enzyme xanthine oxidase needed for uric acid 
formation; it can decrease the oxidative stress 
through free radical scavenging [23].  
G6PD deficient patients may suffer from renal 
impairment from free hemoglobin release that 
can lead to blockage of renal tubules [3, 6, 8, 14]. 
One of our strategies for the preparation of 
patients for operation is to maintain good urinary 
flow using IV mannitol and Furosemide in the day 
before the operation to avoid renal tubular injury 
due to free hemoglobin.  
Careful workup in the perioperative period to 
minimize factors that would cause oxidative 
stress, such as infection, inflammatory response, 
ischemia, low flows on CPB, hypothermia was our 
main strategy for this sector of patients. 
Our results demonstrated that lower 
postoperative hemoglobin levels and hematocrit 
values with more need for blood transfusion and 
higher postoperative total bilirubin and 
reticulocytes in G6PD deficient patients indicating 
more hemolysis of red cells in those patients as 
compared to the control group of patients without 
G6PD deficiency. Also, G6PD deficient patients in 
I
P
e
s
42 Hassan A 
the study had lower levels of Max PaO2 and Min 
PaO2 and longer ventilator time, indicating more 
liability to hypoxia. The above results are 
consistent with the results of Gerrah and 
coworkers [12] who compared the postoperative 
parameters of G6PD deficient patients undergoing 
cardiac surgery using CPB with a control group, 
and they demonstrated that the G6PD deficiency 
group had longer ventilator duration, more 
hypoxia and increased hemolysis with more need 
to blood transfusion. Chowdhry and collaborators 
[11] reported mitral valve replacement using CPB 
for a 38 years old male patient that had G6PD 
deficiency with an uneventful intraoperative and 
postoperative course. They use mannitol and 
allopurinol as free radical scavengers. Kumar [3] 
presented a 30-year-old lady suffering from G6PD 
deficiency, severe mitral stenosis, and severe 
mitral regurgitation with moderate tricuspid 
regurgitation. Mitral valve replacement and 
tricuspid annuloplasty using CPB was done for her 
with an uneventful intraoperative and 
postoperative course using a strategy to minimize 
hemolysis that depends on quick surgery, 
maintenance of normothermic bypass and 
maintaining good urine output. Tas and 
coworkers [7] in a case report of aortic valve 
replacement for a known G6PD deficient patient, 
a 16-year-old suffering from severe aortic 
incompetence as a result of endocarditis, they 
reported that open-heart surgery could be 
applied safely in patients with G6PD with careful 
perioperative management. Ramadass and 
colleagues [24] performed a bidirectional Glenn 
(BDG) procedure with atrial septectomy for a 
G6PD deficient boy who had a ventricular septal 
defect (VSD) and double outlet right ventricle 
(DORV) under CPB. They used mannitol to 
scavenge free radicals and avoid acidosis by 
adding sodium bicarbonate to the prime solution 
with an uneventful outcome. The mortality in 
G6PD deficiency patients in our study was 5%, 
which we consider as an acceptable rate for this 
category of patients. 
Limitations 
The main limitation is the retrospective nature 
of the study with small sample size. However, this 
study design is accepted to study rare conditions. 
Conclusion 
Despite the management strategy, G6PD 
deficient patients undergoing cardiac surgery are 
more liable to hemolysis and hypoxia with more 
need for blood transfusion and longer ventilation 
time, ICU, and hospital stays when compared to 
patients with normal G6PD enzyme activity. 
Further research to improve the outcomes in 
G6PD deficient patients is required. 
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